Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $15.02, for a total transaction of $66,088.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05).

ILLEGAL ACTIVITY WARNING: This piece was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thestockobserver.com/2017/10/13/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4400-shares-of-stock.html.

Several research analysts have recently issued reports on the stock. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday, September 11th. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $24.40.

A number of large investors have recently modified their holdings of ATRA. Voya Investment Management LLC raised its position in Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. State of Wisconsin Investment Board purchased a new position in Atara Biotherapeutics in the 2nd quarter worth $252,000. The Manufacturers Life Insurance Company raised its position in Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. American International Group Inc. raised its position in Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 948 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply